The Quest to Extend the Reach of Checkpoint Inhibitors in Lung Cancer

Nature - United Kingdom
doi 10.1038/d41586-017-08700-9
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Pretreatment Nutritional Status and Response to Checkpoint Inhibitors in Lung Cancer

Lung Cancer Management
2020English

Cardiotoxicity of Immune Checkpoint Inhibitors in Patients With Lung Cancer

Journal of Cardiac Failure
Cardiovascular MedicineCardiology
2019English

2) Lung Cancer Treatment Using Immune Checkpoint Inhibitors

Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine
Medicine
2019English

Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer

Cancer
Cancer ResearchOncology
2017English

Checkpoint Inhibitors in Squamous Non-Small Cell Lung Cancer (NSCLC)

Open Access Journal of Oncology and Medicine
2018English

When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?

Current Treatment Options in Oncology
OncologyPharmacology
2019English

P1.01-69 Validation of the Lung Immune Prognostic Index (LIPI): Useful to Identify Resistance to PD-1 Checkpoint Inhibitors in Pretreated Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors

Oncologist
Cancer ResearchMedicineOncology
2019English

Treatment- And Immune-Related Adverse Events of Immune Checkpoint Inhibitors in Advanced Lung Cancer

Bioscience Reports
BiochemistryCell BiologyMolecular BiologyBiophysics
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy